Diversify Wealth Management LLC Has $4.14 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Diversify Wealth Management LLC increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 3.4% during the third quarter, HoldingsChannel reports. The fund owned 35,792 shares of the company’s stock after acquiring an additional 1,183 shares during the quarter. Diversify Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $4,143,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NVO. 1620 Investment Advisors Inc. bought a new position in Novo Nordisk A/S in the 2nd quarter worth approximately $25,000. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S in the 2nd quarter worth approximately $25,000. Orion Capital Management LLC bought a new position in Novo Nordisk A/S in the 1st quarter worth approximately $26,000. Gilliland Jeter Wealth Management LLC boosted its holdings in Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after buying an additional 120 shares during the period. Finally, Halpern Financial Inc. boosted its holdings in Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after buying an additional 113 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on NVO shares. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 9th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, October 10th. Finally, BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Trading Up 0.6 %

Novo Nordisk A/S stock traded up $0.64 during mid-day trading on Wednesday, hitting $112.62. The company’s stock had a trading volume of 6,700,740 shares, compared to its average volume of 4,320,562. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.94 and a quick ratio of 0.75. The stock has a market cap of $505.39 billion, a price-to-earnings ratio of 38.16, a price-to-earnings-growth ratio of 1.48 and a beta of 0.42. The business has a 50 day moving average price of $125.68 and a 200-day moving average price of $131.19. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing the consensus estimate of $0.71 by ($0.06). The business had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. As a group, analysts forecast that Novo Nordisk A/S will post 3.01 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were paid a dividend of $0.5126 per share. This represents a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 24.66%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.